CPT Code 80307: Presumptive drug test billing guide 2026

Key Takeaways

CPT code 80307 reports presumptive drug tests performed using instrumented chemistry analyzers, chromatography, or mass spectrometry, covering any number of drug classes from a single specimen in one billable unit.

Bill 80307 only once per date of service regardless of how many drug classes are tested; definitive testing codes (G0480-G0483) cannot be separately billed on the same date of service.

Medicare does not reimburse 80307 and G0480 on the same DOS; pass-through billing of drug testing services performed by another entity is prohibited by payers including BCBS.

Pabau’s claims management software helps practices document medical necessity, flag same-day bundling conflicts, and reduce denial rates on 80307 claims before submission.

CPT code 80307 reports a presumptive drug test run on an instrumented chemistry analyzer, covering any number of drug classes from a single specimen and billed once per date of service. It is a qualitative screen: the result shows whether a drug class is present or absent, not the concentration.

The American Medical Association (AMA) descriptor reads: Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (eg, utilizing immunoassay [EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography; includes sample validity testing, per date of service, any number of drug classes.

Pain management practices, substance use disorder programs, and medication-assisted treatment (MAT) practices are the primary settings where 80307 appears on claims.

What CPT code 80307 tests for

80307 screens for the presence or absence of a drug or drug class. It does not confirm the specific drug’s identity or quantify concentration, which is the job of definitive testing. The analyzer technology separates 80307 from the simpler 80305 and 80306 codes.

Common drug classes screened under CPT code 80307 include:

• Amphetamines and methamphetamines
• Barbiturates
• Benzodiazepines
• Buprenorphine
• Cannabinoids (THC)
• Cocaine metabolites
• Fentanyl and analogs
• Methadone
• Opiates (codeine, morphine, hydrocodone, oxycodone)
• Phencyclidine (PCP)
• Tricyclic antidepressants (TCAs)

The code covers any number of drug classes tested in a single encounter. A 10-panel screen and a 20-panel screen are both reported as one unit of 80307. The technology level, not the panel size, determines the correct code.

CPT code 80307 vs 80305 vs 80306: Choosing the right code

The three presumptive drug testing codes are separated by the method used to read results. Choosing the wrong one is the most common reason practices face medical-necessity downcodes on drug screen claims. The table below maps each code to its method:

Key distinction for 80306 vs 80307: 80306 is read by an instrument that assists direct optical observation (the device highlights the color change), while CPT code 80307 requires a full instrumented chemistry analyzer that processes the reaction and reports a digital result. If your practice uses a benchtop analyzer rather than a handheld optical reader, 80307 is the correct code.

Sample validity testing (creatinine, pH, oxidant, specific gravity) is included in all three codes when performed and cannot be separately billed. The same complexity-tier logic governs other screening families; see our guide to ADHD screening CPT codes.

CPT code 80307 vs G0480: Medicare and definitive testing

For Medicare patients, definitive drug testing is billed with HCPCS G-codes, not the CPT 80320-80377 series. The definitive codes are:

• G0480: Definitive drug test, 1-7 drug classes
• G0481: Definitive drug test, 8-14 drug classes
• G0482: Definitive drug test, 15-21 drug classes
• G0483: Definitive drug test, 22+ drug classes
• G0659: Definitive drug test, any number of drug classes (simplified method; for labs not using drug-specific calibration)

The critical billing rule: CPT code 80307 and G0480 cannot both be reimbursed on the same date of service for a Medicare beneficiary. The presumptive screen (80307) and the definitive confirmation (G0480 tier) are mutually exclusive on the same DOS. Per Fidelis Care clinical policy and confirmed by BCBS IL CPCP020 (2026), only one definitive drug testing code is eligible for reimbursement when reported for the same patient on the same date.

Many commercial payers follow the same logic even when they are not bound by Medicare rules. Before submitting both on the same DOS, verify the specific payer’s drug testing policy, which is a frequent point of variation for state Medicaid programs. Practices billing fertility services face a similar payer-specificity challenge, covered in our guide to IVF CPT codes.

Medicare reimbursement for 80307 in 2026

80307 is priced on the Medicare Clinical Laboratory Fee Schedule (CLFS), which sets a single national payment rate. There are no relative value units (RVUs), no geographic or locality adjustment, and no facility versus non-facility split. The current rate is published on the CMS Clinical Laboratory Fee Schedule.

For 2026, the national CLFS rate for 80307 is approximately $62 (about $62.14), and Medicare generally pays in the range of $60 to $80. Because the rate is national, it does not change by MAC jurisdiction or place of service. Confirm the current figure on the CLFS before using it in financial projections, since CMS updates the lab fee schedule annually.

Reimbursement points to keep in mind:

• 80307 is always paid from the Clinical Laboratory Fee Schedule at the single national rate, whether the test is run by a reference lab or the ordering provider’s in-house lab. It is not on the Physician Fee Schedule.
• As a clinical laboratory service, it is not subject to the Part B deductible or coinsurance; Medicare pays the CLFS amount in full.
• 80307 requires a moderate- or high-complexity CLIA certificate. It is not a CLIA-waived test, so it cannot be reported with modifier QW (QW applies to 80305).
• Some Medicare Advantage plans apply separate drug testing reimbursement policies that differ from traditional Medicare.

Because 80307 has no RVUs, RVU and conversion-factor lookup tools do not apply to it. To confirm current payment, look up code 80307 on the CMS Clinical Laboratory Fee Schedule for the current year.

Stop losing revenue to 80307 denials

Pabau's claims management tools help pain management and substance use disorder practices catch same-day bundling conflicts, document medical necessity, and submit cleaner drug testing claims from day one.

Book a demo

Medical necessity and ICD-10 codes

Payers require medical necessity documentation for every 80307 claim, with diagnosis codes linked to the clinical rationale for testing. These ICD-10-CM categories are the ones payers most commonly accept for 80307:

CMS guidance (Medicare Coverage Database articles A56915 and A56818) specifies that diagnosis codes must be coded to the highest level of specificity. Submitting F11.10 when the patient’s documented status is F11.20 (opioid use disorder, moderate, uncomplicated) is a documentation mismatch that auditors flag.

Practices treating patients with mental health conditions such as brief psychotic disorder that require medication monitoring should ensure their ICD-10 codes reflect the treating diagnosis, not just the reason for the screen. Substance use disorder programs that pair testing with structured intake can standardize screening using validated instruments such as the AC-OK screen for co-occurring disorders or an internet addiction test for co-occurring behavioral concerns.

When 80307 is ordered during an evaluation and management visit, such as a new patient office visit, the note for that encounter should carry the ordering rationale. Medical necessity documentation should include:

• The clinical diagnosis supporting the need for monitoring
• Frequency of testing and rationale (e.g., monthly for MAT patients per clinical protocol)
• The provider’s attestation that results will be used to guide treatment decisions
• Any prior test results referenced in the clinical note

Structured clinical documentation saves the most time during audits. Digital intake forms that capture patient consent and clinical rationale at the point of care keep the supporting detail attached to each claim. For practices managing HIPAA obligations alongside billing, the HIPAA compliance checklist for primary care covers the documentation retention rules that apply to drug testing records.

Billing rules and modifiers

These billing rules govern how 80307 is submitted and what triggers a denial.

Once-per-DOS rule

80307 may only be billed once per date of service, regardless of how many drug classes are screened or how many specimens are collected. A 10-panel and a 12-panel run on the same patient on the same day count as one unit of 80307. This is confirmed by both Fidelis Care clinical policy and BCBS IL CPCP020 (2026).

Pass-through billing prohibition

A provider may only bill for services the provider (or the provider’s staff under direct supervision) actually performs. If a practice sends specimens to a reference lab and the lab performs the 80307 analysis, the practice cannot bill 80307 as if it performed the test itself.

BCBS IL CPCP020 (2026) explicitly prohibits pass-through billing. Violating this rule creates compliance exposure beyond simple claim denial. The full scope of HIPAA compliance for medical offices shows where billing and documentation obligations intersect.

Bundling rules

Drug confirmation testing is considered included in CPT codes 80305 through 80307. You cannot bill a separate confirmation code alongside 80307 on the same DOS. Per Moda Health RPM016 policy, any confirmation or definitive testing claimed on the same date as 80307 will be bundled and denied.

Common modifiers

Modifiers for 80307 are relatively uncommon compared to procedure codes, but the following apply in specific scenarios:

• Modifier 59: Distinct procedural service. Use cautiously and only when a payer specifically requests it to unbundle a service that would otherwise be combined. Documentation must clearly support that the service is clinically distinct.
• Modifier QW: Does not apply to 80307. 80307 is a moderate- or high-complexity test; QW (CLIA-waived test) is used with 80305 when a point-of-care screen is run under a CLIA waiver certificate.
• Modifier 91: Repeat clinical diagnostic laboratory test. Used when a test is repeated on the same DOS for a clinical reason (e.g., a dilute specimen requiring retest). This modifier does not override the once-per-DOS rule for routine billing.

Documentation and denial prevention

Most 80307 denials fall into three categories: missing medical necessity, same-day bundling, and pass-through billing errors. A fourth category, frequency violations, is less common but increasingly audited by Medicaid programs.

Documentation the claim needs

• Clinical note dated the same DOS, with the ordering provider’s signature or attestation
• Diagnosis code(s) linked to the medical necessity for drug monitoring
• The specific drug classes or substances tested (or reference to the panel ordered)
• Result of the test and how it informed treatment decisions (for MAT and SUD programs especially)
• Evidence the test was performed in-house if billing under the practice’s NPI (not pass-through)

Appeal strategy for denied 80307 claims

When 80307 claims are denied for medical necessity, the appeal should include:

• A copy of the treating provider’s clinical note documenting the rationale
• Reference to the applicable LCD or payer policy that supports the testing frequency
• A letter from the treating provider explaining how the test result influenced the care plan
• Any prior authorization confirmation, if the payer required it

Practices that use claims management software with built-in denial tracking can identify patterns in 80307 rejections across providers, pinpointing whether denials cluster around a specific ICD-10 code, provider, or payer. That visibility turns reactive denial handling into a repeatable process, the same discipline covered in our guide to CPT code 97014 billing and denial prevention.

Teams comparing systems before they build these checks can start with our roundup of the best medical billing software in the US.

Payer-specific policies

Federal payer rules set the floor. Commercial payers can be more restrictive. These are the most commonly referenced payer-specific positions on 80307:

• Medicare (CMS): Follows the LCD/NCD framework. Article A56915 governs urine drug testing billing and coding. 80307 is covered for medically necessary drug monitoring, with G0480-G0483 required for definitive testing.
• BCBS Illinois (CPCP020, 2026): 80307 appropriate when the test is performed by an instrument chemistry analyzer. Once per DOS. Pass-through billing prohibited. Confirmation testing included and cannot be separately billed.
• Moda Health (RPM016): Confirmation/definitive testing included in 80305-80307. Cannot be separately billed on the same DOS.
• Fidelis Care: 80307 billed once irrespective of the number of drug class procedures or results on any date of service. Only one definitive testing code (G0480) eligible for reimbursement on the same DOS.
• Anthem/ABCBS: Clinical guideline CG-LAB-09 governs drug testing for substance use disorder and chronic pain, addressing adherence monitoring in outpatient settings.
• State Medicaid programs: Vary significantly. Medi-Cal and ForwardHealth Wisconsin both require 80305-80307 and G0480-G0483 for drug testing claims. Always check state-specific fee schedules and coverage policies.

Behavioral health programs that bill alongside drug testing, such as community support services under HCPCS H2015, face the same payer-specific documentation demands. Practices billing across multiple states or payers should maintain a payer-specific policy matrix updated at least quarterly. Automated billing workflows can route claims to payer-specific rule sets before submission, reducing manual policy lookups.

For practices choosing a system to manage documentation across multi-payer environments, the billing-rule flexibility described in our guide to practice management software applies directly to drug testing complexity.

Conclusion

CPT code 80307 denials follow predictable patterns: same-day bundling with G0480, missing medical necessity documentation, pass-through billing errors, and once-per-DOS violations. Each is preventable with the right billing rules in place before submission. For teams new to revenue cycle work, our overview of what medical billing involves covers the fundamentals behind these rules.

Pabau’s claims management software helps practices that bill 80307 regularly build pre-submission checks that catch same-day conflicts, track denial reasons by payer, and document medical necessity at the point of care. To see how it works in a pain management or substance use disorder billing workflow, book a demo with the team.

Continue your research

List Item #1

List Item #2

Frequently Asked Questions